Literature DB >> 25875411

Antegrade Versus Retrograde Approach to Interlocking Nail Fixation of Femoral Diaphyseal Fractures: Is there Difference in Time to Union?

A M Toluse1, I C Ikem, A L Akinyoola, O Esan, J E Asuquo.   

Abstract

BACKGROUND: Antegrade reamed interlocked intramedullary nailing is the treatment of choice forfemoral diaphyseal fractures. More recently, retrograde intramedullary nailing of the femur has been seen as a viable alternative to the antegrade nail.
METHODS: This was a prospective comparative study. Consecutive patients were placed alternately into a study group (retrograde nailing) and a control group (antegrade nailing) in a ratio of 2:1 i.e two retrograde nailing for every antegrade nailing. Forty one fractures had interlocking intramedullary fixation via the retrograde approach (study group), while the control group consisted of twenty fractures that had fixation via the antegrade approach. All were followed up for a minimum period of nine months (range of nine to twenty-four months).
RESULTS: The mean duration of surgery in the retrograde group was 157.07minutes and 137.40 minutes in the antegrade group (p=0.093). The mean duration to fracture union was 16.98±4.71 weeks in the retrograde group and 15.80±5.43 weeks in the antegrade group (p = 0.388). There was no incidence of non-union in the two groups.
CONCLUSION: Retrograde approach compares favourably with antegrade approach for intramedullary interlocking nail fixation of diaphyseal femoral fracture in adults with respect to time of fracture healing.

Entities:  

Year:  2015        PMID: 25875411

Source DB:  PubMed          Journal:  Niger Postgrad Med J


  1 in total

Review 1.  Antegrade versus retrograde nailing techniques and trochanteric versus piriformis intramedullary nailing entry points for femoral shaft fractures: a systematic review and meta-analysis.

Authors:  Nasir Hussain; Farrah Naz Hussain; Corey Sermer; Hera Kamdar; Emil H Schemitsch; Amir Sternheim; Paul Kuzyk
Journal:  Can J Surg       Date:  2017-02       Impact factor: 2.089

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.